Painless Myocardial Ischemia in Diabetic Patients.

Overview

This study aims to investigate the relationship between the concentrations of blood orphanin, norepinephrine and the morbidity of painless myocardial ischemia in patients with diabetes mellitus. Hopefully, the biomarker(s) in the blood of diabetic patients can be found for screening high risk patients in the diabetes sufferers to prevent the painless myocardial ischemia.

Full Title of Study: “Changes of Plasma Orphanin and Norepinephrine Levels in Patients With Painless Myocardial Ischemia and Diabetes Mellitus.”

Study Type

• Study Type: Observational
• Study Design
  • Time Perspective: Prospective
• Study Primary Completion Date: December 30, 2019

Interventions

• Diagnostic Test: ELISA Test
  • The levels of orphanin and norepinephrine in blood of diabetic patients with painless myocardial ischemia requiring interventional therapy and diabetic patients without interventional therapy were measured.

Arms, Groups and Cohorts

• Coronary angiography group
  • In diabetic patients without symptoms of myocardial ischemia, coronary angiography showed no stenosis or stenosis less than 75%.
• Coronary angiographic stent implantation group
  • Coronary angiographic stenosis was more than 75% in diabetic patients without myocardial ischemia symptoms, and coronary stents were implanted.

Clinical Trial Outcome Measures

Primary Measures

• Blood orphanin content
  • Time Frame: 24 hours
  • Blood orphanin levels in painless diabetic patients with myocardial ischemia requiring interventional therapy and diabetic patients without interventional therapy.
• Blood norepinephrine content
  • Time Frame: 24 hours
  • Blood norepinephrine levels in diabetic patients with painless myocardial ischemia requiring interventional therapy and diabetic patients without interventional therapy

Participating in This Clinical Trial

Inclusion Criteria

• Subject has diabetes

Exclusion Criteria

• History of myocardial ischemia
• Symptoms of myocardial ischemia（ECG changes except）

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

• Lead Sponsor
  • Second Hospital of Shanxi Medical University
• Provider of Information About this Clinical Study
  • Principal Investigator: Zheng Guo, professor – Second Hospital of Shanxi Medical University